Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | IDXX | Common Stock | Options Exercise | $1.1M | +5.31K | +76.7% | $206.94 | 12.2K | Nov 10, 2022 | Direct | F1 |
transaction | IDXX | Common Stock | Sale | -$1.09M | -2.66K | -21.7% | $410.02 | 9.58K | Nov 10, 2022 | Direct | F2 |
transaction | IDXX | Common Stock | Sale | -$10.2K | -25 | -0.26% | $406.11 | 9.55K | Nov 10, 2022 | Direct | F3 |
transaction | IDXX | Common Stock | Sale | -$1.07M | -2.63K | -27.53% | $405.21 | 6.92K | Nov 10, 2022 | Direct | F4 |
transaction | IDXX | Common Stock | Options Exercise | $1.53M | +8.57K | +123.74% | $178.26 | 15.5K | Nov 11, 2022 | Direct | |
transaction | IDXX | Common Stock | Sale | -$1.13M | -2.57K | -17.27% | $442.05 | 12.3K | Nov 11, 2022 | Direct | F5 |
transaction | IDXX | Common Stock | Sale | -$1.31M | -3K | -23.21% | $438.00 | 9.92K | Nov 11, 2022 | Direct | |
transaction | IDXX | Common Stock | Sale | -$1.31M | -3K | -30.23% | $436.06 | 6.92K | Nov 11, 2022 | Direct | F6 |
holding | IDXX | Common Stock | 100 | Nov 10, 2022 | by spouse | F7 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | IDXX | Non-Qualified Stock Option (right-to-buy) | Options Exercise | -5.31K | -63.47% | 3.06K | Nov 10, 2022 | Common Stock | 5.31K | $206.94 | Direct | F8, F10 | ||
transaction | IDXX | Non-Qualified Stock Option (right-to-buy) | Options Exercise | -8.57K | -84.42% | 1.58K | Nov 11, 2022 | Common Stock | 8.57K | $178.26 | Direct | F9, F10 |
Id | Content |
---|---|
F1 | Includes a total of 37 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2022, June 30, 2022 and, September 30, 2022. |
F2 | Represents the weighted average price of the shares sold ranging from a low of $410.00 to a high of $410.35 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
F3 | Represents the weighted average price of the shares sold ranging from a low of $406.10 to a high of $406.115 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
F4 | Represents the weighted average price of the shares sold ranging from a low of $405.00 to a high of $405.87 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
F5 | Represents the weighted average price of the shares sold ranging from a low of $442.00 to a high of $442.0125 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
F6 | Represents the weighted average price of the shares sold ranging from a low of $435.00 to a high of $435.21 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
F7 | The reporting person disclaims beneficial interest of the shares of common stock held by her spouse except to the extent of her pecuniary interest therein. |
F8 | Grant of option to buy shares of Issuer common stock that vest in five annual installments beginning February 14, 2020. |
F9 | Grant of option to buy shares of Issuer common stock that vest in five annual installments beginning February 14, 2019. |
F10 | Not applicable. |